Skip to main content
OpenTrials
Completed

NCT Number: NCT04650867

Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomography

Monocentric, prospective observational study to assess bowel inflammation in children with chronic inflammatory bowel disease (IBD) using multispectral optoacoustic tomography (MSOT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Erlangen

Erlangen, Bavaria, 91054, Germany

About this study

Inflammatory bowel diseases (IBD) play a major role in child and adolescent medicine. 25 % of patients with IBD are younger than 18 years of age at diagnosis and 25 % of those are even younger than 10 years of age at disease onset. The incidence of IBD in children and adolescents is 5-11/100 000 in Germany. IBD comprises mainly two entities, namely Crohn's disease (CD) and ulcerative colitis (UC). Patients with CD develop chronic and intermittent transmural inflammation of the gastrointestinal tract, which manifests with symptoms like diarrhea, hematochezia, abdominal pain, fatigue and malnutrition. This often results in weight loss and an increased risk of numerous complications such as the development of fistulas, perforations and intestinal strictures. In addition, growth disturbances and delayed onset of puberty are more frequent. Overall, the course of the disease can only be compared between children and adults to a very limited extent, as the disease often progresses more rapidly and severely in children. Accordingly, the procedure and recommendations for children with CD differ from those of adults. In addition to clinical scores, laboratory chemical parameters (blood count, CrP, calprotectin) and imaging diagnostics (endoscopy, ultrasound, MRT) are available to assess disease activity. However, the latter are only of limited use for routine monitoring due to their invasiveness, the need for sedation and the use of contrast agents. Multispectral Optoacoustic Tomograph (MSOT) on the other hand allows, comparable to sonography, a non-invasive, quantitative imaging of the composition of target tissues in children without sedation. Previous studies have shown that the quantitative determination of hemoglobin provides information on blood flow and inflammatory activity in the bowel of adult patients with Crohn's disease. In this pilot study, the intestinal wall of children will be characterized by MSOT to differentiate between CD, UC, and unclassified inflammatory bowel disease (U-IBD) and to quantify changes and correlate them with routine parameters. This could lead to a new possibility of non-invasive evaluation of disease forms and activity comparable to previous findings in adult patients with CD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CD patients
  • Diagnosis CD or suspected CD at initial diagnosis
  • Indication for endoscopy and sampling (biopsy)
  • UC patients
  • Diagnosis UC or suspected UC at initial diagnosis
  • Indication for endoscopy and sampling (biopsy)
  • U-IBD patients
  • Diagnosis U-IBD or suspected IBD at initial diagnosis
  • Indication for endoscopy and sampling (biopsy)

Exclusion criteria

  • Pregnancy
  • Nursing mothers
  • Unstable patients: Need for continuous cardiopulmonary monitoring (ECG and pulse oximetry)
  • Tattoo in the field of investigation
  • Subcutaneous fat tissue over 3 cm
  • Lack of written consent

Treatment and study plan

Multispectral Optoacoustic Tomography (MSOT)

Device

Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).

Primary outcomes

  1. Quantitative amount of oxygenated/deoxygenated hemoglobin in a.u.

    Time frame: Single time point (1 day)

    Oxygenated/deoxygenated hemoglobin signals in the intestinal/bowel wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)

Secondary outcomes

  1. Quantitative amount of fibrosis/collagen signal in a.u.

    Time frame: Single time point (1 day)

    fibrosis/collagen signals in the intestinal wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)

  2. Quantitative amount of single wavelength signal in a.u.

    Time frame: Single time point (1 day)

    single wavelength signals in the intestinal wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)

  3. Optoacoustic spectrum in a.u.

    Time frame: Single time point (1 day)

    Optoacoustic spectrum in the intestinal wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)

  4. Endoscopic extent of inflammation

    Time frame: Single time point (1 day), +/- 7 days from MSOT Imaging

    Assessment of inflammation in endoscopies within different entities of IBD (CD vs. UC vs. U-IBD)

  5. Histological extent of inflammation and fibrosis

    Time frame: Single time point (1 day), +/- 7 days from MSOT Imaging

    Assessment of inflammation and fibrosis in histological samples from biopsies within different entities of IBD (CD vs. UC vs. U-IBD)

  6. Clinical evaluation

    Time frame: Single time point (1 day)

    Assessement of clinical disease status by PCDAI or PUCAI according to the CED within different entities of IBD (CD vs. UC vs. U-IBD)

  7. Ultrasound

    Time frame: Single time point (1 day), +/- 1 day from MSOT Imaging

    Assessment of disease status by ultrasound within different entities of IBD (CD vs. UC vs. U-IBD)

  8. Laboratory parameters (blood - c-reaktive protein (CrP))

    Time frame: Single time point (1 day), +/- 7 day from MSOT Imaging

    Assessment of disease status by laboratory parameters (CrP) within different entities of IBD (CD vs. UC vs. U-IBD)

  9. Laboratory parameters (stool - Calprotectin)

    Time frame: Single time point (1 day), +/- 14 day from MSOT Imaging

    Assessment of disease status by laboratory parameters (Calprotectin) within different entities of IBD (CD vs. UC vs. U-IBD)

  10. MRI

    Time frame: Single time point (1 day), +/- 14 day from MSOT Imaging

    Assessment of disease status by MRI (if applicable) within different entities of IBD (CD vs. UC vs. U-IBD)

Sponsors and collaborators

Lead sponsor

University of Erlangen-Nürnberg Medical School

Other

Registry information

Acronym: PED_MSOT_IBD

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 3, 2020
Registry last updated
Apr 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.